Our results identify the STAT3-PKM2-HIF-1α/ROS axis as a key determinant of metabolic and phenotypic plasticity in hormone-independent breast and prostate cancers, highlighting its potential as a molecular target for therapeutic modulation of cancer-associated metabolic phenotypes. This evidence concerns the gene STAT3 and cancer.